Meglumine antimoniate (IMMA) (20 mg/kg/d for 20 days) vs placebo (3 tablets/4 times a day
Risk for at least one adverse event per patient · People with American cutaneous and mucocutaneous leishmaniasis
Meglumine antimoniate (IMMA) (20 mg/kg/d for 20 days) probably leads to higher adverse effects (number of participants who had at least one adverse… compared with placebo (3 tablets/4 times a day (moderate certainty).
1 finding from 1 review
- Interventions for American cutaneous and mucocutaneous leishmaniasis 2020 · Cochrane Headline outcomes onlyRR 1.51 [1.17, 1.96]1 study · 134 participantsModerate